On the role of dendritic cells in the pathogenesis of vitiligo

Abstract


The authors give the results of immunohistochemistry studies of the skin of 16 healthy volunteers and 16 patients suffering from
vulgar vitiligo with the determination of the contents of immature (CD1a+) and mature (CD83+) subpopulations of dendritic
cells (DCs) as well as CD4+ and CD8+ lymphocytes in the epidermis and perivascular infiltrates of the derma. They revealed an
increased quantity of CD1a+ and CD83+ DCs in areas of depigmented, peripheral and perifocal normally pigmented skin of vitiligo
foci. DCs with the CD1a+ phenotype were revealed both in the epidermis and in the derma while DCs with the CD83+ phenotype
were revealed in the derma only. A higher quantity of CD4+ and CD8+ lymphocytes than in healthy volunteers was also revealed
along with the increased contents of DCs in all three areas of vitiligo foci. The authors established a strong correlation between
the quantity of CD83+ DCs and CD4+ lymphocytes in the depigmentation zone (r=0.84; Р<0.001). The data obtained prove the
involvement of CD1a+ and CD83+ DCs in the pathogenesis of vitiligo and their participation in the initiation of T-cell response in
the affection foci.

References

  1. Bystryn J.-C. Immune mechanisms in vitiligo. Clin Dermatol 1997; 15: 853-861.
  2. Sehgal V. N., Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol 2006; 45: 583-590.
  3. DellAnna M. L., Picardo M. A review and a new hypothesis for nonimmunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19: 406-411.
  4. Schallreuter K. U., Bahadoran P., Picardo M. et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exper Dermatol 2008; 17: 139-160.
  5. Kemp E. H., Waterman E. A., Weetman A. P. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
  6. Ongenae K., Van Geel N., Naeyaert J.-M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
  7. Van den Wijngaard R. M., Wankowicz-Kalinska A., Pals S. et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81: 8: 1061-1067.
  8. Le Poole I. C., Wankowicz-Kalinska A., Van den Wijngaard R. M. et al. Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol Symp Proc 2004; 9: 1: 68-72.
  9. Le Poole I. C., Van den Wijngaard R. M., Westerhof W. et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148: 4: 1219-1228
  10. Das P. K., Van den Wijngaard R., Wankowicz-Kalinska A. et al. A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol 2001; 22: 3: 130-136.
  11. Rezaei N., Gavalas N. G., Weetman A. P. et al. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venerol 2007; 21: 7: 865-876.
  12. Rashtak S., Pittelkow M. R. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun 2008; 10: 3: 44-58.
  13. Le Poole I. C., Luiten R. M. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmune 2008; 10: 227-243.
  14. Ярилин А. А. Основы иммунологии: Учебник. М.: Медицина, 1999; 608.
  15. Пащенков М. В., Пинегин Б. В. Роль дендритных клеток в ре- гуляции иммунного ответа. Иммунология. 2002; 5: 313-321.
  16. Макаренкова В. П., Кост Н. В., Щурин М. Р. Система дендрит- ных клеток в индукции иммунитета и в патогенезе инфекцион- ных, аутоиммунных и онкологических заболеваний. Иммуно- логия. 2002; 2: 68-76.
  17. Westerhof W., Groot I., Krieg S. R. et al. Langerhans cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venerol 1986; 66: 259-262.
  18. Moncada B., Sandoval M., Amaro R. S. et al. Increased numbers of Langerhans cells in vitiligo. Arch Dermatol 1987; 123: 10: 1267-1268.
  19. Horn T. D. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am. J. Dermatopathol 1997; 19: 4: 400-402.
  20. Hann S. K., Kim Y. S., Yoo J. H., Chun Y. S. Clinical and histopathologic characteristics of trichome vitiligo. J Am Acad Dermatol 2000; 42: 4: 589-596.
  21. Сохибова З. Н. Морфофункциональная характеристика посто- янных и мигрирующих в кожу иммунокомпетентных клеток у больных витилиго в динамике курсового лечения: Автореф. дис… канд. мед. наук. Душанбе, 2000; 21.
  22. Кошевенко Ю. Н. К вопросу о причинах гибели меланоцитов при витилиго. Патоморфологическая картина пораженной кожи (сообщение I) Рос. журн. кож. и венер. болезней. 2000; 1: 53-63.
  23. Пащенков М. В., Пинегин Б. В. Физиология клеток врожденной иммунной системы: дендритные клетки. Иммунология 2006; 6: 368-378.
  24. Prechtel AT, Steinkasserer A. CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007; 299 (2): 59-69.
  25. Prazma CM, Tedder TF. Dendritic cell CD83: a therapeutic target or innocent bystander? Immunol Lett 2008; 15; 115 (1): 1-8.
  26. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002; 312.
  27. Sieling P. A., Jullien D., Dahlem M. et al. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol 1999; 162 (3): 1851-1858.
  28. Koga T., Duan H., Urabe K., Furue M. In situ localization of CD83- positive dendritic cells in psoriatic lesions. Dermatology 2002; 204: 2: 100-103.
  29. Hirano N., Butler M., Xia Z. et al. Engagement of CD83 ligand induces prolonged expansion of CD8+T cells and preferential enrichment for antigen specificity. Blood 2006; 107: 1528-1536.

Statistics

Views

Abstract - 657

PDF (Russian) - 292

PlumX

Article Metrics

Metrics Loading ...

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Proshutinskaya D.V., Volnukhin V.A., Katunina O.R., Rezaikina A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies